Adaptive Biotechnologies Corporation Common Stock (ADPT) is a publicly traded Healthcare sector company. As of May 21, 2026, ADPT trades at $13.94 with a market cap of $2.03B and a P/E ratio of -41.23. ADPT moved +7.64% today. Year to date, ADPT is -13.67%; over the trailing twelve months it is +49.15%. Its 52-week range spans $4.27 to $20.76. Analyst consensus is strong buy with an average price target of $20.17. Rallies surfaces ADPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Adaptive Biotechnologies Raises MRD Revenue Guidance to $260M–$270M After 53% Q1 Growth: Adaptive Biotechnologies reported Q1 revenue of $70.9 million, up 35% year-over-year, driven by MRD business which grew 53% to $67.1 million; clonoSEQ test volume rose 41% to 32,595 tests. The company raised full-year MRD revenue guidance to $260–$270 million and narrowed operating expense forecast to $350–$360 million, while net loss narrowed to $20.0 million.
| Metric | Value |
|---|---|
| Price | $13.94 |
| Market Cap | $2.03B |
| P/E Ratio | -41.23 |
| EPS | $-0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.76 |
| 52-Week Low | $4.27 |
| Volume | 153 |
| Avg Volume | 0 |
| Revenue (TTM) | $295.41M |
| Net Income | $-49.64M |
| Gross Margin | 75.26% |
8 analysts cover ADPT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.17.